Recently, a novel RAIDD-caspase-2-mediated intrinsic cell death pathway was reported in adult T-cell leukemia/lymphoma (ATLL) following treatment with an inhibitor of deacetylase enzymes (LBH589), an anticancer drug, both in vitro and in vivo [116]. The gene discussed is CASP2; the disease is adult T-cell leukemia/lymphoma.